Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R. Welch JS, et al. Among authors: uy gl. Am J Hematol. 2011 Sep;86(9):796-800. doi: 10.1002/ajh.22092. Epub 2011 Aug 3. Am J Hematol. 2011. PMID: 21815182 Free article. Clinical Trial. No abstract available.
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Mrózek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology. Blum W, et al. Leukemia. 2017 Jan;31(1):34-39. doi: 10.1038/leu.2016.252. Epub 2016 Sep 13. Leukemia. 2017. PMID: 27624549 Free PMC article. Clinical Trial.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: uy gl. Blood. 2025 Jan 7:blood.2024025154. doi: 10.1182/blood.2024025154. Online ahead of print. Blood. 2025. PMID: 39775763
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation.
Abboud R, Schroeder MA, Rettig MP, Jayasinghe RG, Gao F, Eisele J, Gehrs L, Ritchey JK, Choi J, Abboud CN, Pusic I, Jacoby MA, Westervelt P, Christopher M, Cashen AF, Ghobadi A, Stockerl-Goldstein K, Uy GL, DiPersio JF. Abboud R, et al. Among authors: uy gl. Blood. 2024 Nov 22:blood.2024026497. doi: 10.1182/blood.2024026497. Online ahead of print. Blood. 2024. PMID: 39576962
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Metzeler KH, Rausch C, Krug U, Sauerland C, Görlich D, Berdel WE, Woermann BJ, Braess J, Spiekermann K, Herold T, Eisfeld AK. Archer KJ, et al. Among authors: uy gl. Innovation (Camb). 2024 Oct 21;5(6):100719. doi: 10.1016/j.xinn.2024.100719. eCollection 2024 Nov 4. Innovation (Camb). 2024. PMID: 39529956 Free PMC article.
151 results